Company: MDCXW
Filing Date: 2025-04-25
Form Type: DRS
Source: 0001062993-25-007956
Chunk: 203

Company: Medicus Pharma Ltd.
Filing Date: 2025-04-25
Form: DRS
Chunk 203
---
 in this offering. The placement agent may engage one or more subagents or selected dealers in connection with this offering.

We are offering on a “best efforts” basis up to 2,550,000 Units, each consisting of one common share and one aarrant.

Each warrant will be exercisable for one common share. The exercise price of each warrant will equal the per Unit offering price hereunder, which we have assumed to be $3.92 based on the closing price of our common shares rounded to the nearest whole cent on the Nasdaq Capital Market on April 23, 2025. The warrants will be immediately exercisable (subject to the beneficial ownership cap) and may be exercised until the fifth anniversary of the date of issuance.

The following table shows the public offering price, placement agent fees and proceeds, before expenses, to us.

|                                 |     | Per  
 Unit |
|:--------------------------------|:----|:-----|
| Public offering price           |     | $    |
| Placement agent fees            |     | $    |
| Proceeds to us, before expenses |     | $    |

We estimate that the total expenses of the offering, including registration, filing and listing fees, printing fees, legal and accounting expenses, expenses for background ground checks, travel and lodging expenses associated with road show trips, but excluding the placement agent fees, will be approximately $250,000, all of which are payable by us.

There is no minimum amount of proceeds that is a condition to closing of this offering. The actual amount of gross proceeds, if any, in this offering could vary substantially from the gross proceeds from the sale of the maximum amount of securities being offered in this prospectus.

Because this is a best-efforts offering, the placement agent does not have an obligation to purchase any securities. This offering will terminate on , 2025, unless we decide to terminate the offering (which we may do at any time in our discretion) prior to that date. We expect that the offering will settle delivery versus payment (“DVP”)/receipt versus payment (“RVP”). Accordingly, we and the placement agent have not made any arrangements to place investor funds in an escrow account or trust account since the placement agent will not receive investor funds in connection with the sale of the securities offered hereunder.

Placement Agent Fees, Commissions and Expenses

Pursuant to the placement agency agreement, we will pay the placement agent, concurrently with each closing of this offering, a cash placement fee equal to seven and one-half percent (